表阿霉素
医学
不利影响
盐酸阿霉素
化疗
养生
药品
乳腺癌
癌症
入射(几何)
临床试验
麻醉
外科
内科学
阿霉素
药理学
光学
物理
作者
Chiemi Ono,Mitsue Yamagami,Rika Kamatani,Makoto Yamamoto,Tomoya Mukouyama,Masakazu Sugimoto,Tateyuki Suzuki,Nobuyuki Kamo,Nobuhiko Seki,Katsumi Eguchi,Tadashi Ikeda
出处
期刊:PubMed
日期:2012-05-01
卷期号:39 (5): 777-81
被引量:1
摘要
Epirubicin hydrochloride(EPI)is well known to cause phlebitis as a typical adverse drug reaction. By preventing the development of severe phlebitis, patients are expected to continue effective chemotherapy with EPI without a decrease in QOL. We have previously reported promising results of a new injection method to prevent phlebitis from occurring during EPI therapy thorough a prospective clinical trial in our hospital(Jpn J Cancer Chemother 36: 969-974, 2009). In the present study, we have compared the conventional injection method(EPI main -route method, n=15)with our new method, which has been consistently practiced at present(EPI sub -route method, n=77). We found that in the EPI main -route method, angialgia/phlebitis developed in 14 of 15 cases(Grade 3, 53. 3%), leading to alteration of the regimen in 3 cases. On the other hand, with the EPI sub -route method, incidence of angialgia/phlebitis was markedly decreased, and only 6 of 77 cases developed these adverse reactions(Grade 3, 0%). One possible explanation for these results is that the reduction of intimal stimulation by the EPI sub -route method might be caused by the dilution and washout of EPI with pre-medication, as well as the shortened infusion times of EPI. Therefore, on the basis of the above hypothesis, we conclude that the EPI sub-route method might be a more effective treatment for the expected prevention of angialgia/phlebitis.
科研通智能强力驱动
Strongly Powered by AbleSci AI